1Cohen M,Demers C,Gurfinkel EP,et al.A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease.Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.N Engl J Med,1997,337:447-452.
2Antman EM,McCabe CH,Gurfinkel EP,et al.Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction.Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.Circulation,1999,100:1593-1601.
3Serebruany VL,Malinin AI,Callahan KP,et al.Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction:the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy.Am Heart J,2003,145:636-642.
4Wallentin L,Goldstein P,Armstrong PW,et al.Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting:the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.Circulation,2003,108:135-142.
5Collet JP,Montalescot G,Lison L,et al.Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris.Circulation,2001,103:658-663.
6Kereiakes DJ,Montalescot G,Antman EM,et al.Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention:an expert consensus.Am Heart J,2002,144:615-624.
7Choussat R,Montalescot G,Collet JP,et al.A unique,low dose of intravenous enoxaparin in elective percutaneous coronary intervention.J Am Coll Cardiol,2002,40:1943-1950.
8Montalescot G,Collet JP,Tanguy ML,et al.Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.Circulation,2004,110:392-398.
